- Email: [email protected]
708 The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use
s251
Abstracts
--
Racial group
*4
*2
Duplication
A freq (W
Ghana 0.00 ians African 0.69
A N=
A freq W)
A N=
A freq A (%) N=
32
3.57
28
0.00
34
144
1.39
144
0.68
146
Ame ricans Chi0.00 nese Japane 0.00 se Cau1.98 casia ns
a3
3.64
154
0.07
154
62
21.21
66
0.00
48
1162
0.60
1162
0.69
1169
707 IMPACTOFTHESITE ANALYSIS OF COCAINE DERMAL SELEGILINE
OFCOLLECTION ONSWEAT IN COMBINATION WITH TRANS-
N. Uemura, AS. Dearborn, R.P. Nath, D.S. Harris, N. Chiang, P. Jacob III, J. Mendelson, and R.T. Jones, Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, CA Sweat analysis may become a useful method to monitor drug use during clinical trials as well as treatment for cocaine dependence. This study investigated the influence of transdermal selegiline on cocaine concentrations in sweat collected from different parts of the body (back or shoulder) over 3-7 days period. Twelve nondependent, cocaine-experienced volunteers received an intravenous dose of cocaine-d5 (2.5 mg/kg) with and without trandermal selegiline (20 mg/day). Sweat cocaine levels were determined using PharmchekTM sweat patches and GC/MS. Seventy-two patches were applied and 5 patches (6.9%) were lost during patch wear. The sensitivity of the sweat test for cocaine was extremely high (100%). The sweat cocaine levels in the
patch declined over 7 days period. Selegiline treatment furth.er reduced cocaine levels over O-24 h. Interestingly, the site of the sweat collection markedly impacted the results of sweat analysis. The cocaine levels in patches from the lower back was 8-fold greater than those from the upper shoulder. These results suggest that sweat analysis is a highly sensitive method for mon:toring cocaine use. However, the results may be affected by collection period, by co-administered drugs, and remarkably, by the site of sweat collection. Supported by NIDA contract NOIDA-4-8306 and NIH RR-00079 (GCRC, UCSF). 708 THERELATIONSHIPBETWEENCOCAINECRAVING, PSYCHOSOCIAL TREATMENT, AND SUBSEQUENT CAINE USE
CO-
R. D. Weiss, M. L. Griffin, C. Mazurick, R. Gallop, and B. Berkman, Harvard Medical School, Alcohol and Drug Program, McLean Hospital, Belmont, MA and University of Pennsylvania, Philadelphia, PA Regular measurement of craving during treatment can monitor patients’ clinical status and potentially assess their risk for drug use in the near future. Effective treatment, however, could reduce the correlation between craving and subsequent drug use by helping patients abstain despite high craving. In the NIDA Collaborative Cocaine Treatment Study, which compared four behavioral treatments for cocaine dependence, we administered a simple 3-question craving questionnaire weekly to see whether it predicted cocaine use in the ensuing week. Controlling for the previous week’s cocaine use, we found that each one-point increase on the craving questionnaire composite score increased the likelihood of cocaine use in the next week by 10%; when patients were asked to rate their likelihood of use if in a former drug-using situation, a one-point increase corresponded with a 20% increased likelihood of use in the next week. However, we found an interaction between treatment condition and patients,’ perceived likelihood of use in a drug-using situation; among patients receiving Individual Drug Counseling (IDC), which produced the best cocaine use outcomes in the study, greater craving did not predict great’er cocaine use in the next week. These results suggest that one mechanism of action of IDC is its ability to help patients to cope effectively with craving.
Abstracts
--
Racial group
*4
*2
Duplication
A freq (W
Ghana 0.00 ians African 0.69
A N=
A freq W)
A N=
A freq A (%) N=
32
3.57
28
0.00
34
144
1.39
144
0.68
146
Ame ricans Chi0.00 nese Japane 0.00 se Cau1.98 casia ns
a3
3.64
154
0.07
154
62
21.21
66
0.00
48
1162
0.60
1162
0.69
1169
707 IMPACTOFTHESITE ANALYSIS OF COCAINE DERMAL SELEGILINE
OFCOLLECTION ONSWEAT IN COMBINATION WITH TRANS-
N. Uemura, AS. Dearborn, R.P. Nath, D.S. Harris, N. Chiang, P. Jacob III, J. Mendelson, and R.T. Jones, Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, CA Sweat analysis may become a useful method to monitor drug use during clinical trials as well as treatment for cocaine dependence. This study investigated the influence of transdermal selegiline on cocaine concentrations in sweat collected from different parts of the body (back or shoulder) over 3-7 days period. Twelve nondependent, cocaine-experienced volunteers received an intravenous dose of cocaine-d5 (2.5 mg/kg) with and without trandermal selegiline (20 mg/day). Sweat cocaine levels were determined using PharmchekTM sweat patches and GC/MS. Seventy-two patches were applied and 5 patches (6.9%) were lost during patch wear. The sensitivity of the sweat test for cocaine was extremely high (100%). The sweat cocaine levels in the
patch declined over 7 days period. Selegiline treatment furth.er reduced cocaine levels over O-24 h. Interestingly, the site of the sweat collection markedly impacted the results of sweat analysis. The cocaine levels in patches from the lower back was 8-fold greater than those from the upper shoulder. These results suggest that sweat analysis is a highly sensitive method for mon:toring cocaine use. However, the results may be affected by collection period, by co-administered drugs, and remarkably, by the site of sweat collection. Supported by NIDA contract NOIDA-4-8306 and NIH RR-00079 (GCRC, UCSF). 708 THERELATIONSHIPBETWEENCOCAINECRAVING, PSYCHOSOCIAL TREATMENT, AND SUBSEQUENT CAINE USE
CO-
R. D. Weiss, M. L. Griffin, C. Mazurick, R. Gallop, and B. Berkman, Harvard Medical School, Alcohol and Drug Program, McLean Hospital, Belmont, MA and University of Pennsylvania, Philadelphia, PA Regular measurement of craving during treatment can monitor patients’ clinical status and potentially assess their risk for drug use in the near future. Effective treatment, however, could reduce the correlation between craving and subsequent drug use by helping patients abstain despite high craving. In the NIDA Collaborative Cocaine Treatment Study, which compared four behavioral treatments for cocaine dependence, we administered a simple 3-question craving questionnaire weekly to see whether it predicted cocaine use in the ensuing week. Controlling for the previous week’s cocaine use, we found that each one-point increase on the craving questionnaire composite score increased the likelihood of cocaine use in the next week by 10%; when patients were asked to rate their likelihood of use if in a former drug-using situation, a one-point increase corresponded with a 20% increased likelihood of use in the next week. However, we found an interaction between treatment condition and patients,’ perceived likelihood of use in a drug-using situation; among patients receiving Individual Drug Counseling (IDC), which produced the best cocaine use outcomes in the study, greater craving did not predict great’er cocaine use in the next week. These results suggest that one mechanism of action of IDC is its ability to help patients to cope effectively with craving.